ArticleWorld journal of gastrointestinal surgery2025
Therapeutic outcomes and predictors of efficacy for endoscopic variceal ligation plus propranolol in liver cirrhosis-related upper gastrointestinal bleeding.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirrhosis-related upper gastrointestinal bleeding (UGIB) poses a fatal risk, and endoscopic ligation as a sole intervention shows inadequate effectiveness.
aimTo evaluate the therapeutic efficacy of endoscopic variceal ligation (EVL) plus propranolol
methodsThis study enrolled 99 consecutive patients with cirrhosis presenting with acute UGIB between January 2024 and January 2025. Participants were allocated to either the control group (
resultsCompared with the control group, the research group demonstrated significantly better outcomes, including higher overall treatment efficacy, greater reductions in PVF and SVF, shorter hemostasis time and hospital stay, and lower rebleeding rates. Univariate analysis demonstrated significant associations between treatment efficacy and age, cirrhosis duration, Child-Pugh grade, bleeding duration, and treatment approach in patients with cirrhosis complicated with acute UGIB. Multivariate logistic regression identified three independent risk factors for poor outcomes, namely, advanced age (> 55 years), prolonged cirrhosis duration (≥ 4 years), and delayed bleeding intervention (> 24 hours).
conclusionThe EVL plus propranolol regimen demonstrates significant efficacy in treating UGIB in cirrhosis, outperforming EVL alone in improving hemodynamics (PVF/SVF), shortening hemostasis and hospitalization duration, and reducing rebleeding rates. Moreover, advanced age, prolonged disease duration, and longer bleeding times are independent risk factors for poor therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.